PhaseBio Pharmaceuticals Long Term Debt

PhaseBio Pharmaceuticals (PHAS) currently reports a long-term debt of $870K as of June 2022. That compares with $5.4M in the prior-year period — down 83.8% year over year. Use the charts on this page to explore PhaseBio Pharmaceuticals's long-term debt history and peer comparisons.

PhaseBio Pharmaceuticals's long-term debt decreased from $5.4M to $870K — a 83.8% year-over-year decrease (period ending June 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

PhaseBio Pharmaceuticals reported $870K in long-term debt as of June 2022. That compares with $5.4M in the prior-year period — down 83.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $870K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for PhaseBio Pharmaceuticals, and consider following PHAS for alerts when major investors trade the stock.

PhaseBio Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $870K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PHAS with unrelated industries.